Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

27.6%

8 terminated/withdrawn out of 29 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

52%

15 trials in Phase 3/4

Results Transparency

55%

11 of 20 completed trials have results

Key Signals

11 with results6 terminated

Enrollment Performance

Analytics

Phase 3

15(51.7%)

Phase 2

13(44.8%)

N/A

1(3.4%)

29Total

Phase 3(15)

Phase 2(13)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT04489381Phase 3Terminated

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Role: lead

NCT05157243Phase 3Withdrawn

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Role: lead

NCT05157269Phase 3Withdrawn

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Role: lead

NCT04343248Phase 3Terminated

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Role: lead

NCT04359680Phase 3Completed

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Role: lead

NCT04486313Phase 3Completed

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Role: lead

NCT03905655Phase 2Completed

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

Role: lead

NCT01227421Phase 2Completed

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Role: lead

NCT03336619Phase 3Completed

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Role: lead

NCT03605862Phase 3Completed

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Role: lead

NCT01056380Phase 2Terminated

Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza

Role: lead

NCT02612922Phase 3Completed

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Role: lead

NCT01610245Phase 3Completed

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Role: lead

NCT00384527Phase 3Terminated

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Role: lead

NCT00495391Phase 2Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Role: lead

NCT00637923Phase 2Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Role: lead

NCT00302640Phase 2Completed

Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Role: lead

NCT00130390Phase 2Terminated

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Role: lead

NCT01328925Phase 2Completed

Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children

Role: lead

NCT01326338Phase 3Completed

Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

Role: lead